Enveric Biosciences, Inc. Annual Report: A Simple Guide

I’ve put together this guide to help you understand how Enveric Biosciences performed this year. My goal is to turn complex filing data into plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Enveric is a drug discovery company. They aren't selling medicine yet. Instead, they are in the lab creating new, psychedelic-inspired treatments for mental health conditions like depression and anxiety.

Their platform, Psybrary™, holds over 1,000 unique molecules. Their goal is to create drugs that provide the benefits of psychedelic therapy—like improved mood—without the "trip." This would allow these treatments to be used in standard doctor’s offices rather than under specialized, multi-hour supervision.

2. Financial performance: The "Spending" Phase

Enveric is currently in a "spending" phase rather than a "making money" phase. For the year ended December 31, 2025, the company reported zero revenue.

They recorded a loss of approximately $14.2 million. This resulted from spending $8.1 million on research and development and $6.1 million on general business operations. The company is actively using its cash reserves to fund lab studies and the regulatory process required for FDA drug applications.

3. Major wins and challenges

The company’s primary focus is maintaining its research pipeline. Because they do not yet generate revenue, they rely on raising capital to fund operations. In 2025, they raised about $6.5 million through the sale of additional shares.

This strategy allows research to continue, but it results in dilution. When the company issues new shares to raise cash, the ownership percentage of existing shareholders decreases. As of March 2026, there were approximately 1.89 million shares outstanding, reflecting an increase driven by the need to fund ongoing operations.

4. Financial health

Enveric relies on external funding to sustain its business. As of December 31, 2025, the company held approximately $4.2 million in cash. Given a monthly burn rate of roughly $1.1 million, the company has a limited operational runway. To continue its research programs, the company will need to secure additional capital or establish a partnership deal within the next 6 to 9 months.

5. Key risks

• The Biotech Gamble: The company’s value is tied to the success of its lead drug, EB-003, in human trials. If these trials do not yield positive results, the company lacks alternative revenue-generating products.
• Dilution: The ongoing need to raise cash through equity offerings will likely continue to dilute the value of current holdings.
• Competition: Enveric competes with well-funded pharmaceutical companies that possess greater financial resources and more extensive experience with the FDA approval process.
• Regulatory Risk: The regulatory landscape for psychedelic-inspired medicine is still evolving. Changes in FDA requirements could increase the costs and timeframes necessary to bring a drug to market.

6. Future outlook

The company is moving forward with the development of EB-003, with plans to file for FDA approval to begin human trials in 2026. They are also advancing a new series of molecules known as EVM401. A primary objective for the coming year is to secure a partnership with a larger pharmaceutical company. Such a partnership would provide non-dilutive capital and serve as a validation of their drug discovery platform.

Note: This is a high-risk, early-stage company. You are not buying a business with steady profits; you are investing in the potential success of their scientific research.